Search results | merck kgaa

Reports

Partnering Agreements with Merck KGaA

This report provides all the information you require to better understand Merck KGaA / Merck Serono and its partnering interests and activities over the past seven years.

Insights

Merck KgaA partnering

Merck KGaA is a top pharmaceutical company based in Darmstadt, Germany

Partnering with Merck KgaA / Merck Serono: Your best partner

Merck KgaA / Merck Serono is a top pharma company active in partnering, licensing and M&A in biopharmaceuticals, consumer healthcare and research equipment

Merck KGaA: Partnering activity 2005-2013

Merck KGaA and Merck Serono announced over 136 partnering / licensing deals since 2005, with 28 deals in 2007 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in oncology

Merck KGaA: M&A activity 2005-2013

Merck KGaA has announced 8 M&A deals since 2005, with the lead deal being the acquisition of Serono

Merck KGaA / Merck Serono: Company Profile

Merck KGaA, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

No major pharma deals for Merck KGaA until 2013

Germany’s Merck KGaA, a big pharma company will refrain from major pharma deals until the end of next year to focus on cost cuts and job reduction, its Chief Executive said on Friday

Dealmakers weekly review – February 6 2012 – Merck KgaA, Threshold, Bill and Melinda Gates Foundation, AstraZenenca, Actavis

The week was relatively quiet until the end of week announcement by Merck KGaA of a $550 million partnership with Threshold for the co-development and commercialization of TH-302

Merck KGaA and Millipore combine to establish EMD Millipore and strengthen presence within the Life Science sector

Merck KGaA has acquired the outstanding shares of common stock of Millipore Corporation for $107 per share in cash or a total transaction of $7.2 billion.

Merck Serono partnering

Merck Serono is a subsidiary of Merck KgaA

Merck hunts for smaller drug developers for acquisition

German healthcare group Merck KGaA is looking for acquisitions and collaborations with start-ups to grow its drugs business in the United States, a senior Merck official said.

Events

Sorry, your search returned no results.


Deals

Merck KGaA returns Sym004 to Symphogen

Merck KGaA is conducting an ongoing assessment of its pipeline assets and has decided to return the rights of Sym004 to Symphogen for further development

Merck KgaA and Pfizer join forces for MSB0010718C development

Merck KGaA has entered into a global agreement with Pfizer to co-develop and co-commercialize MSB0010718C

Merck KGaA and BeiGene collaborate in co-promotion agreement

BeiGene and Merck KGaA, a top big pharma company  have entered into a global licensing, co-development, co promotion and commercialization agreement for BeiGene-283.

Merck Serono Ventures nets $77.4 in financing facility from Merck KGaA

Merck announced that it will increase its commitment to its strategic corporate venture capital fund Merck Serono Ventures to € 100 million of financing.

Merck KGaA closes $2.6 billion re financing

Merck KGaA, a big pharma company, announced the successful closing of a € 2 billion syndicated loan financing.

Merck KGaA co-operates with Symphogen in worldwide pharma licensing pact

Merck KGaA, a top big pharma company announced the signing of a worldwide pharma licensing agreement with Symphogen, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

M&A: Merck KGaA’s EMD Miilipore acquires Biochrom

EMD Millipore, a Merck KGaA subsidiary has entered into definitive M&A agreement to acquire Biochrom, a Berlin based cell culture media specialist company.

Merck KGaA signs worldwide pharma licensing with PDS Biotechnology for nanotechnology platform

PDS Biotechnology have entered into an exclusive worldwide pharma licensing agreement with Merck KGaA for use of PDS Biotechnology’s novel Versamune nanotechnology platform in two of Merck’s investigational antigen-specific cancer immunotherapies currently in pre-clinical development.

MDxHealth inks pharma partners deal with Merck KGaA for cancer Dx

MDxHealth  has inked a development and commercialization pharma partners deal with Merck KGaA, looking to market a companion diagnostic test for one of the drugmaker’s cancer treatments.

No major pharma deals for Merck KGaA until 2013

Germany’s Merck KGaA, a big pharma company will refrain from major pharma deals until the end of next year to focus on cost cuts and job reduction, its Chief Executive said on Friday

cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif
cabannerad300x150new4gif
rauconbadgejpg
e78banner300x150animgif